What did @mickyandrade_ actually say?
The creator says a peptide combination of GHK-Cu, BPC-157, and TB-500 replaced all her supplements, reversed hair thinning, improved skin texture, eliminated joint inflammation, and sped up muscle recovery. All of this, she claims, happened in roughly four weeks. She closes by offering to connect followers with her doctor.
To her credit, she says "this is not medical advice" and "I'm just an entrepreneur" twice. But those disclaimers don't do much work when you follow them with "if I was you I will give it a try" and an offer to refer viewers to your personal physician. That's a soft sales pitch with a legal fig leaf. The claim that inflammation is "gone, gone forever" after four weeks is the kind of language that should make any skeptical reader slow down.
She also consistently mispronounces BPC-157 as "VPC 157" and calls the peptides "Popeye," which appears to be her branding shorthand for the platform or product she's using.
Does the science back this up?
Partially, but the gap between what the research shows and what she claims is significant. GHK-Cu has the strongest evidence of the three for skin applications. BPC-157 and TB-500 have real preclinical data, but almost none of it comes from controlled human trials.
GHK-Cu (copper peptide) has been studied for skin remodeling and collagen synthesis. Pickart and Margolina (2018, Biomolecules) reviewed evidence showing GHK-Cu stimulates collagen and glycosaminoglycan synthesis in vitro and in some small human studies. The anti-inflammatory and wound-healing properties are reasonably supported at the cellular level. Hair growth effects exist in some studies but are modest and mostly in topical or in vitro settings.
BPC-157 is a synthetic peptide derived from a human gastric protein. Animal studies, primarily in rats, show accelerating tendon, ligament, and gut healing. Sikiric et al. (2018, Current Neuropharmacology) document multiple rodent healing studies. There are no published randomized controlled trials in humans as of this writing.
TB-500 (Thymosin Beta-4) has immune-modulating and tissue repair properties studied in cardiac and corneal contexts. Goldstein and Kleinman (2015, Annals of the New York Academy of Sciences) summarize its regenerative biology, but again, human clinical trial data is thin.
What did they get wrong (or right)?
She got the general mechanism directionally right: these peptides do interact with pathways involved in repair and collagen production. That part isn't invented. Where the wheels come off is in the certainty and the timeline.
Saying inflammation is "gone, gone forever" after four weeks is inaccurate by any clinical standard. Even if these peptides contributed to reduced inflammation, four weeks is not a long enough window to make that determination, and "forever" has no scientific basis whatsoever. This is the kind of claim that gives peptide therapy a credibility problem.
The claim that this "replaced" all her vitamins and supplements is also unsupported. These peptides serve different mechanistic functions than, say, biotin for hair or vitamin D for immune regulation. Replacing a broad supplement stack with three peptides assumes a scope of action that isn't documented in the literature.
On the positive side, she correctly identifies GHK-Cu as relevant to collagen and skin quality, and BPC-157 and TB-500 as relevant to recovery and repair. That's not wrong. It's just dramatically oversimplified.
What should you actually know?
These are not FDA-approved drugs for cosmetic or anti-inflammatory use. BPC-157 and TB-500 are research peptides, and their use in compounded injectable form sits in a regulatory gray area in the United States. In 2023, the FDA placed BPC-157 on its list of substances that cannot be compounded, though enforcement has been inconsistent.
Injecting peptides carries real risks: infection at injection sites, hormonal interactions, and unknown long-term effects from combinations that have never been tested together in humans. A "glow stack" sounds benign. An unregulated injectable combination with no long-term human safety data is a different framing of the same thing.
The offer to "hook you up with my doctor" is worth flagging. Physician referrals through social media influencers are not a substitute for an independent clinical evaluation. If you're curious about peptide therapy, talk to a licensed provider who has no financial relationship with the person who recommended them.
- GHK-Cu has the most skin-relevant human evidence of the three, though most studies are small.
- BPC-157 and TB-500 have no published randomized human trials for the uses described here.
- Regulatory status of these peptides as compounded injectables is contested and actively changing.
- Four weeks is not enough time to establish that any intervention has resolved chronic inflammation.